Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

586 articles

Showing 1–2 of 2 articles · Keyword: combination therapy Clear keyword

Frontiers in pharmacology2026ReviewDrug Delivery

1. Overcoming adaptive resistance in non-small cell lung cancer: integrating targeted therapies, immunotherapy synergy, and nanocarrier delivery

Ding L, Staskiewicz A, Kao J, Wang X

Lung cancer is the leading cause of cancer death, characterized by high mortality rates, tumor adaptation and heterogeneity, and immune evasion mechanisms. Despite recent advancements in chemotherapy, radiation, and surgery, survival rates for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)…

Read the article
Frontiers in oncology2026ReviewNon-viral Gene DeliveryDrug Delivery

2. Progress on therapeutic mRNA vaccines for cancer

Wu S, Liao H, Zhang W

Therapeutic mRNA vaccines are a clinically validated cancer immunotherapy platform using in vitro transcribed mRNA encoding tumor antigens to induce durable anti-tumor immunity. Advances in mRNA engineering, lipid nanoparticle (LNP) delivery, and immunomodulatory combinations have propelled this approach from…

Read the article
Articles | Brilliant Blue Biosciences